Cat. No.: HY-13605

Cytarabine

(Synonyms: Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; Ara-C)

100 Cited Publications

Customer Review

Based on 100 publication(s) in Google Scholar

Cytarabine, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC₅₀ of 16 nM. Cytarabine has antiviral effects against HSV. Cytarabine shows anti-orthopoxvirus activity.

For research use only. We do not sell to patients.

Purity: 99.98%
CAS No.: 147-94-4
Formula: C₉H₁₃N₃O₅
Molecular Weight:243.22

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Cytarabine Chemical Structure

CAS No.: 147-94-4

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (100)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

Microbial Metabolite

DNA Polymerase

HSV-1

All DNA/RNA Synthesis Isoforms :

All HSV Isoforms :

All Endogenous Metabolite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
143B	IC₅₀	16.88 μM Compound: Cytarabine	Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay	[PMID: 27073055]
143B	IC₅₀	2.06 μM Compound: Cytarabine	Cytotoxicity against human 143B cells after 72 hrs by SRB assay Cytotoxicity against human 143B cells after 72 hrs by SRB assay	[PMID: 27073055]
A-375	IC₅₀	>410 μM Compound: ara-c	Tested in vitro against A-375 cell line human melanoma Tested in vitro against A-375 cell line human melanoma	[PMID: 8277499]
A549	IC₅₀	620 μM Compound: cytarabine	Cytotoxicity against A549 cells after 72 hrs by SRB assay Cytotoxicity against A549 cells after 72 hrs by SRB assay	[PMID: 17419604]
A549	IC₅₀	1.9 μM Compound: 1, ara-C	Cytotoxicity against human A549 cells by sulforhodamine B method Cytotoxicity against human A549 cells by sulforhodamine B method	[PMID: 19691349]
A549	GI₅₀	0.2 μM Compound: Ara-C	Growth inhibition of human A549 cells after 24 hrs by WST-1 assay Growth inhibition of human A549 cells after 24 hrs by WST-1 assay	[PMID: 22264170]
A549	IC₅₀	1.9 μM Compound: 2, Ara-C	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 24956556]
A549	IC₅₀	1.2 μM Compound: Ara-C	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
A549	IC₅₀	1.75 μM Compound: Ara-C	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by SRB assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by SRB assay	[PMID: 29906687]
A549	IC₅₀	3.47 μM Compound: ara-C	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
A549	IC₅₀	0.83 μM Compound: ara-C	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
A549	IC₅₀	49.27 μg/mL Compound: CAR	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 35963130]
A549	IC₅₀	202.57 μM Compound: CAR	Anticancer activity against human A549 cells incubated for 48 hrs by MTT assay Anticancer activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 38516604]
A549	IC₅₀	1.9 μM Compound: AraC	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 38716896]
AMML	IC₅₀	2.3 μM Compound: ara-C	Compound was tested for the inhibition of AMML (acute myelomonocytic leukemia) Compound was tested for the inhibition of AMML (acute myelomonocytic leukemia)	[PMID: 3761322]
B16	IC₅₀	0.24 μg/mL Compound: Ara-C	In vitro inhibitory activity against Mouse melanoma (B16) cell line. In vitro inhibitory activity against Mouse melanoma (B16) cell line.	[PMID: 1995905]
B16	IC₅₀	30.62 μM Compound: Cytarabine	Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay	[PMID: 21620529]
B16	IC₅₀	49.22 μM Compound: Cytarabine	Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay	10.1039/C0MD00208A
BALL-1	GI₅₀	0.08 μM Compound: Ara-C	Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay	[PMID: 22264170]
Bel-7402	IC₅₀	34.2 μM Compound: Ara-C	Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay	[PMID: 20692841]
Bone marrow cell	GI₅₀	64.1 μM Compound: Cytarabine	Growth inhibition of human bone marrow cells Growth inhibition of human bone marrow cells	[PMID: 29995404]
CAKI-1	IC₅₀	>5 μM Compound: Ara-C	In vitro cytotoxicity was evaluated against renal CAKI-1 cells In vitro cytotoxicity was evaluated against renal CAKI-1 cells	[PMID: 10780904]
CCRF S-180	ED₅₀	0.2 μM Compound: ara-C	Concentration required to inhibit replication of S-180 cell lines by 50% after 72 hr incubation Concentration required to inhibit replication of S-180 cell lines by 50% after 72 hr incubation	[PMID: 1652024]
CCRF S-180	ED₅₀	0.2 μM Compound: ara-C	Effective dose to inhibit the replication of S180 cell line in vitro. Effective dose to inhibit the replication of S180 cell line in vitro.	[PMID: 1995894]
CCRF S-180	IC₅₀	25.43 μM Compound: Cytarabine	Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay	[PMID: 21620529]
CCRF S-180	IC₅₀	40.33 μM Compound: Cytarabine	Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay	10.1039/C0MD00208A
CCRF-CEM	GI₅₀	0.09 μM Compound: Ara-C	In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM without hPAP (0.2 unit/mL) In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM without hPAP (0.2 unit/mL)	[PMID: 11597404]
CCRF-CEM	GI₅₀	0.0998 μM Compound: Ara-C	In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL) In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL)	[PMID: 11597404]
CCRF-CEM	ED₅₀	0.006 μM Compound: ara-C	Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation	[PMID: 1652024]
CCRF-CEM	ED₅₀	120 μM Compound: ara-C	Concentration required to inhibit replication of CCRF-CEM deoxycytidine kinase deficient variant CCRF-CEM(dCK-) Concentration required to inhibit replication of CCRF-CEM deoxycytidine kinase deficient variant CCRF-CEM(dCK-)	[PMID: 1652024]
CCRF-CEM	IC₅₀	0.001 μM Compound: AraC, cytarabine	Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay	[PMID: 19674903]
CCRF-CEM	EC₅₀	0.00561 μM Compound: cytarabine	Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
CCRF-CEM	EC₅₀	0.0228 μM Compound: cytarabine	Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
CCRF-CEM	IC₅₀	0.024 μM Compound: cytarabine	Cytotoxicity against human CEM cells after 2 days Cytotoxicity against human CEM cells after 2 days	[PMID: 19910080]
CCRF-CEM	IC₅₀	0.065 μg/mL Compound: ara-C	Concentration required for 50% inhibition of cell growth of CCRF CEM leukemic cell lines in human. Concentration required for 50% inhibition of cell growth of CCRF CEM leukemic cell lines in human.	[PMID: 1992123]
CCRF-CEM	ED₅₀	0.005 μM Compound: ara-C	Inhibit the replication of CCRF-CEM cell line in vitro. Inhibit the replication of CCRF-CEM cell line in vitro.	[PMID: 1995894]
CCRF-CEM	IC₅₀	0.32 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human T-cell acute lymphoblastoid leukemia (CCRF CEM) cell line. In vitro inhibitory activity against Human T-cell acute lymphoblastoid leukemia (CCRF CEM) cell line.	[PMID: 1995905]
CCRF-CEM	IC₅₀	0.024 μM Compound: ara-C, cytarabine	Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 48 hrs Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 48 hrs	[PMID: 20000418]
CCRF-CEM	IC₅₀	0.006 μM Compound: Ara-C	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
CCRF-CEM	IC₅₀	0.065 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human T-cell acute lymphoblastoid leukemic CCRFCEM cell lines. In vitro inhibitory effect on growth of human T-cell acute lymphoblastoid leukemic CCRFCEM cell lines.	[PMID: 3373480]
CCRF-CEM	IC₅₀	6.0 x 10^-7 M Compound: Ara-C	Cytotoxicity against CCRF-CEM human leukemic lymphoblastoid cell lines Cytotoxicity against CCRF-CEM human leukemic lymphoblastoid cell lines	[PMID: 6827546]
CCRF-CEM	IC₅₀	0.09 μM Compound: 6	In vitro cytotoxicity of compounds were determined on Inhibition of human leukemia cell line(CCRF-CEM). In vitro cytotoxicity of compounds were determined on Inhibition of human leukemia cell line(CCRF-CEM).	[PMID: 8917645]
CCRF-CEM	IC₅₀	0.0037 μM Compound: araC	Compound was evaluated for its antiproliferative activity on human T-lymphocyte CEM cells Compound was evaluated for its antiproliferative activity on human T-lymphocyte CEM cells	10.1016/S0960-894X(97)00044-9
CCRF-CEM/ara-C	IC₅₀	0.0001 M Compound: Ara-C	Cytotoxicity against CCRF-CEM/ara-C human leukemic lymphoblastoid cell lines Cytotoxicity against CCRF-CEM/ara-C human leukemic lymphoblastoid cell lines	[PMID: 6827546]
CCRF-CEM/ara-C	IC₅₀	0.1 mM Compound: Ara-C	Cytotoxicity against CCRF-CEM/ara-C human leukemic lymphoblastoid cell lines Cytotoxicity against CCRF-CEM/ara-C human leukemic lymphoblastoid cell lines	[PMID: 6827546]
CCRF-HSB-2	IC₅₀	0.15 μM Compound: ara-C	Growth inhibition of human CCRF-HSB-2 cells by MTT assay Growth inhibition of human CCRF-HSB-2 cells by MTT assay	[PMID: 17049252]
CCRF-HSB-2	IC₅₀	0.047 μg/mL Compound: Ara-C	Antitumor activity against human CCRF-HSB2 cells by modified MTT assay Antitumor activity against human CCRF-HSB2 cells by modified MTT assay	[PMID: 17644399]
CCRF-HSB-2	IC₅₀	0.047 μg/mL Compound: Ara-C	Antitumor activity against human CCRF-HSB2 cells by MTT assay Antitumor activity against human CCRF-HSB2 cells by MTT assay	[PMID: 17962027]
CCRF-HSB-2	IC₅₀	0.017 μg/mL Compound: Ara-C	Antitumor activity against human CCRF-HSB2 cells by MTT assay Antitumor activity against human CCRF-HSB2 cells by MTT assay	[PMID: 18723355]
CCRF-HSB-2	IC₅₀	0.017 μg/mL Compound: AraC	Growth inhibition of human CCRF-HSB-2 cells by MTT method Growth inhibition of human CCRF-HSB-2 cells by MTT method	[PMID: 18819815]
CCRF-HSB-2	IC₅₀	0.0086 μg/mL Compound: araC	Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells. Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.	[PMID: 9216836]
CML/BC	IC₅₀	0.21 μM Compound: ara-C	Compound was tested for the inhibition of CML/BC(chronic myeloid leukemia, blast crisis) Compound was tested for the inhibition of CML/BC(chronic myeloid leukemia, blast crisis)	[PMID: 3761322]
COLO 320	IC₅₀	0.04 μM Compound: ara-c	Tested in vitro against colo-320 human colon adenocarcinoma Tested in vitro against colo-320 human colon adenocarcinoma	[PMID: 8277499]
DLD-1	IC₅₀	>5 μM Compound: Ara-C	In vitro cytotoxicity was evaluated against colon DLD-1 cells In vitro cytotoxicity was evaluated against colon DLD-1 cells	[PMID: 10780904]
Glioblastoma cell line	IC₅₀	>100 μM Compound: ara-C	Compound was tested for the inhibition of glioblastoma Compound was tested for the inhibition of glioblastoma	[PMID: 3761322]
H22	IC₅₀	25.98 μM Compound: Cytarabine	Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay	[PMID: 21620529]
H22	IC₅₀	37.82 μM Compound: Cytarabine	Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay	10.1039/C0MD00208A
HCT-116	IC₅₀	5.3 μM Compound: 1, ara-C	Cytotoxicity against human HCT116 cells by sulforhodamine B method Cytotoxicity against human HCT116 cells by sulforhodamine B method	[PMID: 19691349]
HCT-116	IC₅₀	0.1 μM Compound: Ara-C	Antitumor activity against human HCT116 cells after 24 hrs by MTT assay Antitumor activity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 20211564]
HCT-116	GI₅₀	0.12 μM Compound: Ara-C	Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay	[PMID: 22264170]
HCT-116	IC₅₀	5.3 μM Compound: 2, Ara-C	Cytotoxicity against human HCT116 cells by SRB assay Cytotoxicity against human HCT116 cells by SRB assay	[PMID: 24956556]
HCT-116	IC₅₀	2.42 μM Compound: Ara-C	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
HCT-116	IC₅₀	4.4 μM Compound: Ara-C	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by SRB assay Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by SRB assay	[PMID: 29906687]
HCT-116	IC₅₀	5.3 μM Compound: AraC	Cytotoxicity against human HCT-116 cells Cytotoxicity against human HCT-116 cells	[PMID: 38716896]
HeLa	IC₅₀	0.23 μg/mL Compound: cytosine arabinoside	Cytotoxicity against human HeLa S3 cells Cytotoxicity against human HeLa S3 cells	[PMID: 10425135]
HeLa	ED₅₀	0.05 μg/mL Compound: AraC	Cytotoxicity against human HeLa cells after 48 hrs by Coulter counter analysis Cytotoxicity against human HeLa cells after 48 hrs by Coulter counter analysis	[PMID: 178873]
HeLa	IC₅₀	464.433 μM Compound: Ara-C, Cytarabine	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 19321234]
HeLa	IC₅₀	0.26 μM Compound: ara-C, cytarabine	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs	[PMID: 20000418]
HeLa	GI₅₀	0.18 μM Compound: Ara-C	Growth inhibition of human HeLa cells after 24 hrs by WST-1 assay Growth inhibition of human HeLa cells after 24 hrs by WST-1 assay	[PMID: 22264170]
HeLa	IC₅₀	3.54 μM Compound: Cytarabine	Cytotoxicity against human HeLa cells after 72 hrs by SRB assay Cytotoxicity against human HeLa cells after 72 hrs by SRB assay	[PMID: 23867603]
HeLa	IC₅₀	3.54 μM Compound: Cytarabine	Cytotoxicity against human HeLa cells after 72 hrs by SRB assay Cytotoxicity against human HeLa cells after 72 hrs by SRB assay	[PMID: 27073055]
HeLa	IC₅₀	3.54 μM Compound: ara-C	Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
HeLa	IC₅₀	0.95 μM Compound: ARA	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 29886320]
HeLa	IC₅₀	3.54 μM Compound: ara-C	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
HeLa S3	ED₅₀	2.13 μg/mL Compound: cytosine arabinoside	Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
HepG2	IC₅₀	0.2 μM Compound: Ara-C	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 20692841]
HepG2	IC₅₀	26.23 μM Compound: Cytarabine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21620529]
HepG2	IC₅₀	2.86 μM Compound: Cytarabine	Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay	[PMID: 27073055]
HepG2	IC₅₀	2.86 μM Compound: ara-C	Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
HepG2	IC₅₀	2.86 μM Compound: ara-C	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
HepG2	IC₅₀	38.1 μM Compound: Cytarabine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	10.1039/C0MD00208A
HL-60	IC₅₀	0.08 μM Compound: citarabine	In vitro inhibitory concentration against proliferation of HL60 cells In vitro inhibitory concentration against proliferation of HL60 cells	[PMID: 12877593]
HL-60	IC₅₀	0.35 μM Compound: citarabine	In vitro concentration required to induce apoptosis in HL60R cells In vitro concentration required to induce apoptosis in HL60R cells	[PMID: 12877593]
HL-60	IC₅₀	0.76 μM Compound: ara-C	Inhibitory activity against HL-60 (human, promyelocytic leukemia) cell line Inhibitory activity against HL-60 (human, promyelocytic leukemia) cell line	[PMID: 12954073]
HL-60	IC₅₀	0.118 μM Compound: Ara-C, Cytarabine	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 19321234]
HL-60	EC₅₀	0.6572 μM Compound: cytarabine	Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
HL-60	IC₅₀	>0.1 μg/mL Compound: ara-C	Concentration required for 50% inhibition of cell growth of HL60 leukemic cell lines in human. Concentration required for 50% inhibition of cell growth of HL60 leukemic cell lines in human.	[PMID: 1992123]
HL-60	IC₅₀	>0.1 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human promyelocytic leukemia (HL-60) cell line. In vitro inhibitory activity against Human promyelocytic leukemia (HL-60) cell line.	[PMID: 1995905]
HL-60	IC₅₀	0.049 μM Compound: Ara-C	Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
HL-60	IC₅₀	0.185 μM Compound: Cytarabine	Antiproliferative activity against human HL60 cells Antiproliferative activity against human HL60 cells	[PMID: 30114661]
HL-60	ED₅₀	0.047 μM Compound: ara-C	Anticancer activity was evaluated for the compound against parent promyelocytic leukemia cell line (HL-60-GHPRT+/dCK+) Anticancer activity was evaluated for the compound against parent promyelocytic leukemia cell line (HL-60-GHPRT+/dCK+)	[PMID: 3027329]
HL-60	ED₅₀	30 μM Compound: ara-C	Anticancer activity of the compound against ara-C resistant promyelocytic leukemia cell line that is Cyd-kinase deficient (HL-60-HGPRT-/dCK-) is determined Anticancer activity of the compound against ara-C resistant promyelocytic leukemia cell line that is Cyd-kinase deficient (HL-60-HGPRT-/dCK-) is determined	[PMID: 3027329]
HL-60	IC₅₀	0.13 μM Compound: ara-C	Compound was tested for the inhibition of human HL60 Leukemia Compound was tested for the inhibition of human HL60 Leukemia	[PMID: 3761322]
HL-60	IC₅₀	0.029 μg/mL Compound: ara-C	The cytotoxic activity in HL-60 cells The cytotoxic activity in HL-60 cells	[PMID: 9371251]
HL60/MX2	EC₅₀	0.2612 μM Compound: cytarabine	Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
HOS-TE85	IC₅₀	2.6 μg/mL Compound: 2	In vitro inhibitory effect measured against human osteosarcoma MNNG-HOS tumor cells In vitro inhibitory effect measured against human osteosarcoma MNNG-HOS tumor cells	[PMID: 2002478]
HOS-TE85	IC₅₀	10.7 μM Compound: ara-c	Tested in vitro against MNNG/HOS cell line human osteosarcoma Tested in vitro against MNNG/HOS cell line human osteosarcoma	[PMID: 8277499]
HT-1080	IC₅₀	0.13 μg/mL Compound: 2	In vitro inhibitory effect measured against human fibrosarcoma HT1080 tumor cells In vitro inhibitory effect measured against human fibrosarcoma HT1080 tumor cells	[PMID: 2002478]
HT-1080	IC₅₀	0.53 μM Compound: ara-c	Tested in vitro against HT1080 cell line human fibrosarcoma Tested in vitro against HT1080 cell line human fibrosarcoma	[PMID: 8277499]
HT-29	IC₅₀	66 nM Compound: cytosine arabinoside	Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay	[PMID: 2778449]
HUVEC	GI₅₀	0.23 μM Compound: Ara-C	Growth inhibition of HUVEC cells after 72 hrs by WST-1 assay Growth inhibition of HUVEC cells after 72 hrs by WST-1 assay	[PMID: 22264170]
Jurkat E6.1	IC₅₀	0.018 μM Compound: Cytarabine	Antiproliferative activity against human Jurkat E6-1 cells Antiproliferative activity against human Jurkat E6-1 cells	[PMID: 30114661]
K562	IC₅₀	500 nM Compound: ara-c	Inhibition of cell growth against human myeloid leukemia K562(S) cells Inhibition of cell growth against human myeloid leukemia K562(S) cells	[PMID: 10560743]
K562	IC₅₀	500 mM Compound: ara-C	Antiproliferative activity against human K562 cells Antiproliferative activity against human K562 cells	[PMID: 18571290]
K562	IC₅₀	0.05 μM Compound: 1, ara-C	Cytotoxicity against human K562 cells by sulforhodamine B method Cytotoxicity against human K562 cells by sulforhodamine B method	[PMID: 19691349]
K562	IC₅₀	3.2 μg/mL Compound: ara-C	Concentration required for 50% inhibition of cell growth of K562 leukemic cell lines in human. Concentration required for 50% inhibition of cell growth of K562 leukemic cell lines in human.	[PMID: 1992123]
K562	IC₅₀	33.5 μM Compound: Ara-C	Cytotoxicity against human K562 cells after 24 hrs by MTT assay Cytotoxicity against human K562 cells after 24 hrs by MTT assay	[PMID: 20692841]
K562	IC₅₀	24.29 μM Compound: Cytarabine	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 21620529]
K562	IC₅₀	14 μM Compound: Ara-C	Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
K562	IC₅₀	0.05 μM Compound: 2, Ara-C	Cytotoxicity against human K562 cells by SRB assay Cytotoxicity against human K562 cells by SRB assay	[PMID: 24956556]
K562	IC₅₀	3.2 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human chronic myelogenous leukemic K562 cell lines. In vitro inhibitory effect on growth of human chronic myelogenous leukemic K562 cell lines.	[PMID: 3373480]
K562	IC₅₀	0.05 μM Compound: AraC	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 38716896]
K562	IC₅₀	43.61 μM Compound: Cytarabine	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	10.1039/C0MD00208A
KATO III stomach cancer cell line	IC₅₀	>100 μg/mL Compound: ara-C	Concentration required for 50% inhibition of human lung squamous cell carcinoma KATO III solid cell lines. Concentration required for 50% inhibition of human lung squamous cell carcinoma KATO III solid cell lines.	[PMID: 1992123]
KATO III stomach cancer cell line	IC₅₀	>100 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human gastric carcinoma (KATO III) cell line. In vitro inhibitory activity against Human gastric carcinoma (KATO III) cell line.	[PMID: 1995905]
KATO III stomach cancer cell line	IC₅₀	>410 μM Compound: ara-c	Tested in vitro against KATO-III human stomach adenocarcinoma Tested in vitro against KATO-III human stomach adenocarcinoma	[PMID: 8277499]
KATO III stomach cancer cell line	IC₅₀	0.3 μM Compound: ara-C	Tested for in vitro cytotoxicity against KATO III human stomach adenocarcinoma cell line Tested for in vitro cytotoxicity against KATO III human stomach adenocarcinoma cell line	[PMID: 8277500]
KB	IC₅₀	0.81 μg/mL Compound: cytosine arabinoside	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 10425135]
KB	IC₅₀	0.7 μM Compound: ara-C	Growth inhibition of human KB cells by MTT assay Growth inhibition of human KB cells by MTT assay	[PMID: 17049252]
KB	IC₅₀	0.23 μg/mL Compound: Ara-C	Antitumor activity against human KB cells by modified MTT assay Antitumor activity against human KB cells by modified MTT assay	[PMID: 17644399]
KB	IC₅₀	0.23 μg/mL Compound: Ara-C	Antitumor activity against human KB cells by MTT assay Antitumor activity against human KB cells by MTT assay	[PMID: 17962027]
KB	ED₅₀	2.84 μg/mL Compound: cytosine arabinoside	Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
KB	IC₅₀	0.14 μg/mL Compound: Ara-C	Growth inhibition of human KB cells by MTT assay Growth inhibition of human KB cells by MTT assay	[PMID: 18055068]
KB	IC₅₀	0.73 μg/mL Compound: Ara-C	Antitumor activity against human KB cells by MTT assay Antitumor activity against human KB cells by MTT assay	[PMID: 18723355]
KB	IC₅₀	0.42 μg/mL Compound: AraC	Growth inhibition of human KB cells by MTT method Growth inhibition of human KB cells by MTT method	[PMID: 18819815]
KB	IC₅₀	30.5 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human oral epidermoid carcinoma (KB) cell line. In vitro inhibitory activity against Human oral epidermoid carcinoma (KB) cell line.	[PMID: 1995905]
KB	ED₅₀	0.99 μg/mL Compound: Cytosine arabinoside	Cytotoxicity against human KB cells assessed as inhibition of protein biosynthesis Cytotoxicity against human KB cells assessed as inhibition of protein biosynthesis	[PMID: 21194944]
KB	IC₅₀	0.99 μg/mL Compound: Cytarabine	Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay	[PMID: 21945463]
KB	IC₅₀	4.07 μM Compound: Cytarabine	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 23867603]
KB	IC₅₀	4.07 μM Compound: Cytarabine	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 27073055]
KB	IC₅₀	4.07 μM Compound: ara-C	Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
KB	IC₅₀	4.07 μM Compound: ara-C	Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
KB	IC₅₀	2.3 μM Compound: ara-c	Tested in vitro inhibitory activity against human oral epidermoid carcinoma KB cells Tested in vitro inhibitory activity against human oral epidermoid carcinoma KB cells	[PMID: 8277499]
KB	IC₅₀	0.64 μM Compound: ara-C	Tested for in vitro cytotoxicity against KB human oral epidermoid carcinoma cell line Tested for in vitro cytotoxicity against KB human oral epidermoid carcinoma cell line	[PMID: 8277500]
KHOS-321H	IC₅₀	0.27 μg/mL Compound: 2	In vitro inhibitory effect measured against human osteosarcoma KHOS-321H tumor cells In vitro inhibitory effect measured against human osteosarcoma KHOS-321H tumor cells	[PMID: 2002478]
KKLS	IC₅₀	>410 μM Compound: ara-c	Tested in vitro against KKLS human stomach adenocarcinoma Tested in vitro against KKLS human stomach adenocarcinoma	[PMID: 8277499]
L02	IC₅₀	0.17 μM Compound: ARA	Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 29886320]
L02	IC₅₀	0.21 μM Compound: ARA	Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay	[PMID: 30852384]
L1210	IC₅₀	0.17 μM Compound: Ara-C	Anticancer activity carried out in vitro against murine leukemia L1210 Anticancer activity carried out in vitro against murine leukemia L1210	[PMID: 11356110]
L1210	ED₅₀	0.1 μM Compound: ara-C	Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay	[PMID: 118258]
L1210	IC₅₀	0.01 μM Compound: 1	Inhibition of L1210 lymphoid leukemia cells 48 hr after administration (length of preincubation=0 hr) Inhibition of L1210 lymphoid leukemia cells 48 hr after administration (length of preincubation=0 hr)	[PMID: 1527783]
L1210	IC₅₀	0.01 μM Compound: 1	Inhibition of L1210 lymphoid leukemia cells 72 hr after administration (length of preincubation=0 hr) Inhibition of L1210 lymphoid leukemia cells 72 hr after administration (length of preincubation=0 hr)	[PMID: 1527783]
L1210	IC₅₀	0.1 μM Compound: 1	Inhibition of L1210 lymphoid leukemia cells 24 hr after administration (length of preincubation=0 hr) Inhibition of L1210 lymphoid leukemia cells 24 hr after administration (length of preincubation=0 hr)	[PMID: 1527783]
L1210	ED₅₀	0.05 μM Compound: ara-C	Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation	[PMID: 1652024]
L1210	ED₅₀	2.76 μg/mL Compound: cytosine arabinoside	Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
L1210	IC₅₀	0.036 μM Compound: ara-C	Inhibitory concentration on multidrug-resistant L1210 leukemia cells. Inhibitory concentration on multidrug-resistant L1210 leukemia cells.	[PMID: 1906107]
L1210	IC₅₀	0.036 μM Compound: ara-C	Inhibitory concentration on parentral (sensitive) L1210 leukemia cells. Inhibitory concentration on parentral (sensitive) L1210 leukemia cells.	[PMID: 1906107]
L1210	IC₅₀	103 μM Compound: AraC, cytarabine	Cytotoxicity against deoxycytidine kinase deficient and nucleoside analogue-resistant mouse L1210 10K cells after 3 days by MTT assay Cytotoxicity against deoxycytidine kinase deficient and nucleoside analogue-resistant mouse L1210 10K cells after 3 days by MTT assay	[PMID: 19674903]
L1210	IC₅₀	0.0004 μM Compound: AraC, cytarabine	Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay	[PMID: 19674903]
L1210	IC₅₀	0.4 nM Compound: AraC, cytarabine	Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay	[PMID: 19674903]
L1210	IC₅₀	0.024 μM Compound: cytarabine	Cytotoxicity against mouse L1210 cells after 2 days Cytotoxicity against mouse L1210 cells after 2 days	[PMID: 19910080]
L1210	IC₅₀	0.097 μg/mL Compound: ara-C	Concentration required for 50% inhibition of cell growth of L1210 leukemic cell lines in mouse. Concentration required for 50% inhibition of cell growth of L1210 leukemic cell lines in mouse.	[PMID: 1992123]
L1210	IC₅₀	0.08 μM Compound: araC	Inhibitory activity against murine leukemia L1210 cells Inhibitory activity against murine leukemia L1210 cells	[PMID: 1992143]
L1210	ED₅₀	0.05 μM Compound: ara-C	Effective dose to inhibit the replication of L1210 cell line in vitro. Effective dose to inhibit the replication of L1210 cell line in vitro.	[PMID: 1995894]
L1210	IC₅₀	0.024 μM Compound: ara-C, cytarabine	Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation after 48 hrs Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation after 48 hrs	[PMID: 20000418]
L1210	ED₅₀	0.03 μM Compound: ara-C	Inhibition of thymidylate synthase in L1210 cells Inhibition of thymidylate synthase in L1210 cells	[PMID: 3027329]
L1210	IC₅₀	0.097 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of mouse leukemic L1210 cell lines. In vitro inhibitory effect on growth of mouse leukemic L1210 cell lines.	[PMID: 3373480]
L1210	ED₅₀	0.19 μM Compound: ara-C	In vitro cytotoxicity with cleavage by phosphodiesterase-I concentration for 50% loss of viability was determined at 72 hours. In vitro cytotoxicity with cleavage by phosphodiesterase-I concentration for 50% loss of viability was determined at 72 hours.	[PMID: 3968680]
L1210	ED₅₀	0.1 μM Compound: ara-C	In vitro antiproliferative activity was measured in mouse myeloma L1210 cell line In vitro antiproliferative activity was measured in mouse myeloma L1210 cell line	[PMID: 7143370]
L1210	IC₅₀	0.05 μM Compound: ara-c	Tested in vitro inhibitory activity against murine leukemia L1210 Tested in vitro inhibitory activity against murine leukemia L1210	[PMID: 8277499]
L1210	IC₅₀	0.12 μM Compound: ara-C	Tested in vitro for cytotoxicity against L1210 leukemia cell line in mouse Tested in vitro for cytotoxicity against L1210 leukemia cell line in mouse	[PMID: 8277500]
L1210	IC₅₀	0.031 μM Compound: araC	Tested for its antiproliferative activity on murine leukemia L1210 cells Tested for its antiproliferative activity on murine leukemia L1210 cells	10.1016/S0960-894X(97)00044-9
Lewis lung carcinoma cell line	IC₅₀	5.6 μM Compound: ara-C	Tested for in vitro cytotoxicity against LLC Lewis lung carcinoma cell line Tested for in vitro cytotoxicity against LLC Lewis lung carcinoma cell line	[PMID: 8277500]
MCF7	IC₅₀	1.03 μM Compound: Ara-C	Anticancer activity carried out in vitro against breast carcinoma MCF-7 Anticancer activity carried out in vitro against breast carcinoma MCF-7	[PMID: 11356110]
MCF7	IC₅₀	0.004 μM Compound: AraC, cytarabine	Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay	[PMID: 19674903]
MCF7	IC₅₀	0.04 μM Compound: AraC, cytarabine	Cytotoxicity against deoxynucleoside analogue-resistant human MCF7 1K cells overexpressing ribonucleotide reductase after 3 days by MTT assay Cytotoxicity against deoxynucleoside analogue-resistant human MCF7 1K cells overexpressing ribonucleotide reductase after 3 days by MTT assay	[PMID: 19674903]
MCF7	IC₅₀	>=100 μM Compound: Ara-C	Antitumor activity against human MCF7 cells after 24 hrs by MTT assay Antitumor activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 20211564]
MCF7	IC₅₀	0.93 μg/mL Compound: Cytarabine	Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay	[PMID: 21945463]
MCF7	IC₅₀	3.82 μM Compound: Cytarabine	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 23867603]
MCF7	IC₅₀	3.82 μM Compound: Cytarabine	Cytotoxicity against human MCF7cells after 72 hrs by SRB assay Cytotoxicity against human MCF7cells after 72 hrs by SRB assay	[PMID: 27073055]
MCF7	IC₅₀	3.82 μM Compound: ara-C	Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
MCF7	IC₅₀	>20 μM Compound: Cytarabine	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay	[PMID: 35665692]
MCF7	IC₅₀	0.62 μM Compound: ara-c	Tested in vitro against MCF-7 human breast adenocarcinoma Tested in vitro against MCF-7 human breast adenocarcinoma	[PMID: 8277499]
MDA-MB-231	IC₅₀	1.37 μM Compound: Ara-C	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
MDA-MB-231	IC₅₀	10.49 μM Compound: Ara-C	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by SRB assay	[PMID: 29906687]
MES-SA	IC₅₀	1.7 μM Compound: AraC, cytarabine	Cytotoxicity against deoxynucleoside analogue-sensitive human MESSA cells after 3 days by MTT assay Cytotoxicity against deoxynucleoside analogue-sensitive human MESSA cells after 3 days by MTT assay	[PMID: 19674903]
MKN-28	IC₅₀	4.5 μg/mL Compound: 2	In vitro inhibitory effect measured against human stomach adenocarcinoma MKN-28 tumor cells In vitro inhibitory effect measured against human stomach adenocarcinoma MKN-28 tumor cells	[PMID: 2002478]
MKN-45	IC₅₀	57.6 μM Compound: ara-c	Tested in vitro against MKN-45 human stomach adenocarcinoma Tested in vitro against MKN-45 human stomach adenocarcinoma	[PMID: 8277499]
MOLT-3	ED₅₀	2.67 μg/mL Compound: cytosine arabinoside	Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
MOLT-4	IC₅₀	0.65 μM Compound: Ara-C	Anticancer activity carried out in vitro against human T-lymphocyte Molt4/C8 Anticancer activity carried out in vitro against human T-lymphocyte Molt4/C8	[PMID: 11356110]
MOLT-4	IC₅₀	0.056 μg/mL Compound: ara-C	Concentration required for 50% inhibition of cell growth of MOLT-4 leukemic cell lines in human. Concentration required for 50% inhibition of cell growth of MOLT-4 leukemic cell lines in human.	[PMID: 1992123]
MOLT-4	IC₅₀	0.056 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human T-cell acute lymphoblastic leukemia (MOLT-4) cell line. In vitro inhibitory activity against Human T-cell acute lymphoblastic leukemia (MOLT-4) cell line.	[PMID: 1995905]
MOLT-4	IC₅₀	1 μM Compound: Ara-C	Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay	[PMID: 20211564]
MOLT-4	IC₅₀	0.056 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human T-cell acute lymphoblastic leukemic MOLT 4 cell lines. In vitro inhibitory effect on growth of human T-cell acute lymphoblastic leukemic MOLT 4 cell lines.	[PMID: 3373480]
MOLT-4	IC₅₀	4.0 x 10^-7 M Compound: Ara-C	Cytotoxicity against MOLT-4 human leukemic lymphoblastoid cell lines Cytotoxicity against MOLT-4 human leukemic lymphoblastoid cell lines	[PMID: 6827546]
MOLT-4	IC₅₀	0.03 μM Compound: araC	Compound was evaluated for its antiproliferative activity on human T-lymphocyte Molt4/C8 cells Compound was evaluated for its antiproliferative activity on human T-lymphocyte Molt4/C8 cells	10.1016/S0960-894X(97)00044-9
MPC-11	ED₅₀	0.99 μM Compound: ara-C	In vitro antiproliferative activity was measured in mouse myeloma MPC-11 cell line In vitro antiproliferative activity was measured in mouse myeloma MPC-11 cell line	[PMID: 7143370]
MV4-11	IC₅₀	3.36 μM Compound: AraC	Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay	[PMID: 20153646]
NCC	IC₅₀	0.13 μg/mL Compound: 2	In vitro inhibitory effect measured against human renal cell carcinoma NCC-nu tumor cells In vitro inhibitory effect measured against human renal cell carcinoma NCC-nu tumor cells	[PMID: 2002478]
NCI-H23	IC₅₀	1 μM Compound: Ara-C	In vitro cytotoxicity was evaluated against lung NCI-H23 cells; 1 x 10E1 In vitro cytotoxicity was evaluated against lung NCI-H23 cells; 1 x 10E1	[PMID: 10780904]
NCI-H460	IC₅₀	0.1 μM Compound: Ara-C	Antitumor activity against human H460 cells after 24 hrs by MTT assay Antitumor activity against human H460 cells after 24 hrs by MTT assay	[PMID: 20211564]
NHDF	IC₅₀	4.99 μM Compound: ara-C	Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
NHDF	IC₅₀	4.99 μM Compound: ara-C	Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
Non-small cell lung cancer cell line	IC₅₀	34 μM Compound: ara-C	Compound was tested for the inhibition of non- small cell lung cancer Compound was tested for the inhibition of non- small cell lung cancer	[PMID: 3761322]
NUGC-3	GI₅₀	0.25 μM Compound: Ara-C	Growth inhibition of human NUGC3 cells after 24 hrs by WST-1 assay Growth inhibition of human NUGC3 cells after 24 hrs by WST-1 assay	[PMID: 22264170]
OST	IC₅₀	>410 μM Compound: ara-c	Tested in vitro against OST human osteosarcoma Tested in vitro against OST human osteosarcoma	[PMID: 8277499]
P388	IC₅₀	0.14 μM Compound: Ara-C	Anticancer activity carried out in vitro against murine leukemia P388 Anticancer activity carried out in vitro against murine leukemia P388	[PMID: 11356110]
P388	ED₅₀	0.02 μM Compound: ara-C	Concentration required to inhibit replication of P388 cell lines by 50% after 72 hr incubation Concentration required to inhibit replication of P388 cell lines by 50% after 72 hr incubation	[PMID: 1652024]
P388	ED₅₀	0.02 μM Compound: ara-C	Effective dose to inhibit the replication of P388 cell line in vitro. Effective dose to inhibit the replication of P388 cell line in vitro.	[PMID: 1995894]
P388	IC₅₀	1233 nM Compound: cytosine arabinoside	Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay	[PMID: 2778449]
PBMC	IC₅₀	181 μM Compound: Cytarabin	Cytotoxicity against human PBMC cells assessed as inhibition of cell growth incubated for 24 to 48 hrs by MTT assay Cytotoxicity against human PBMC cells assessed as inhibition of cell growth incubated for 24 to 48 hrs by MTT assay	[PMID: 38064359]
PC10	IC₅₀	>100 μg/mL Compound: ara-C	Concentration required for 50% inhibition of human lung squamous cell carcinoma PC10 solid cell lines. Concentration required for 50% inhibition of human lung squamous cell carcinoma PC10 solid cell lines.	[PMID: 1992123]
PC10	IC₅₀	>100 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human lung squamous cell carcinoma (PC-10) cell line. In vitro inhibitory activity against Human lung squamous cell carcinoma (PC-10) cell line.	[PMID: 1995905]
PC10	IC₅₀	>100 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human lung squamous cell carcinoma cell lines (PC10). In vitro inhibitory effect on growth of human lung squamous cell carcinoma cell lines (PC10).	[PMID: 3373480]
PC-13	IC₅₀	>100 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human lung large-cell carcinoma (PC-13) cell line. In vitro inhibitory activity against Human lung large-cell carcinoma (PC-13) cell line.	[PMID: 1995905]
PC-13	IC₅₀	>410 μM Compound: ara-c	Tested in vitro against PC-13 human lung large cell carcinoma Tested in vitro against PC-13 human lung large cell carcinoma	[PMID: 8277499]
PC-14	IC₅₀	>100 μg/mL Compound: ara-C	Concentration required for 50% inhibition of human lung squamous cell carcinoma PC14 solid cell lines. Concentration required for 50% inhibition of human lung squamous cell carcinoma PC14 solid cell lines.	[PMID: 1992123]
PC-14	IC₅₀	>100 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human lung adenocarcinoma (PC-14) cell line. In vitro inhibitory activity against Human lung adenocarcinoma (PC-14) cell line.	[PMID: 1995905]
PC-3	IC₅₀	55.9 μM Compound: 1, ara-C	Cytotoxicity against human PC3 cells by sulforhodamine B method Cytotoxicity against human PC3 cells by sulforhodamine B method	[PMID: 19691349]
PC-3	IC₅₀	55.9 μM Compound: 2, Ara-C	Cytotoxicity against human PC3 cells by SRB assay Cytotoxicity against human PC3 cells by SRB assay	[PMID: 24956556]
PC-3	IC₅₀	50.51 μM Compound: Ara-C	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
PC-3	IC₅₀	48.4 μM Compound: Ara-C	Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by SRB assay	[PMID: 29906687]
PC-3	IC₅₀	0.81 μM Compound: ara-C	Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
PC-3	IC₅₀	55.9 μM Compound: AraC	Cytotoxicity against human PC-3 cells Cytotoxicity against human PC-3 cells	[PMID: 38716896]
PC-6	IC₅₀	50 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human lung small-cell carcinoma (PC-6) cell line. In vitro inhibitory activity against Human lung small-cell carcinoma (PC-6) cell line.	[PMID: 1995905]
PC-6	IC₅₀	50 μg/mL Compound: 2	In vitro inhibitory effect measured against human lung small-cell carcinoma PC-6 tumor cells In vitro inhibitory effect measured against human lung small-cell carcinoma PC-6 tumor cells	[PMID: 2002478]
PC-8	IC₅₀	0.28 μg/mL Compound: 2	In vitro inhibitory effect measured against human lung adenocarcinoma PC-8 tumor cells In vitro inhibitory effect measured against human lung adenocarcinoma PC-8 tumor cells	[PMID: 2002478]
PC-8	IC₅₀	1.1 μM Compound: ara-c	Tested in vitro against PC-8 human lung adenocarcinoma Tested in vitro against PC-8 human lung adenocarcinoma	[PMID: 8277499]
PC-9	IC₅₀	1.6 μg/mL Compound: 2	In vitro inhibitory effect measured against human lung adenocarcinoma PC-9 tumor cells In vitro inhibitory effect measured against human lung adenocarcinoma PC-9 tumor cells	[PMID: 2002478]
PC-9	IC₅₀	6.6 μM Compound: ara-c	Tested in vitro against PC-9 human lung adenocarcinoma Tested in vitro against PC-9 human lung adenocarcinoma	[PMID: 8277499]
QG-95	IC₅₀	>410 μM Compound: ara-c	Tested in vitro against QG-95 human squamous cell carcinoma Tested in vitro against QG-95 human squamous cell carcinoma	[PMID: 8277499]
RPMI 6410	IC₅₀	6.0 x 10^-6 M Compound: Ara-C	Cytotoxicity against RPMI-6410 human leukemic lymphoblastoid cell lines Cytotoxicity against RPMI-6410 human leukemic lymphoblastoid cell lines	[PMID: 6827546]
RS4-11	IC₅₀	0.26 μM Compound: AraC	Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay	[PMID: 20153646]
SAOS-2	IC₅₀	2.7 μg/mL Compound: 2	In vitro inhibitory effect measured against human osteosarcoma SAOS-2 tumor cells In vitro inhibitory effect measured against human osteosarcoma SAOS-2 tumor cells	[PMID: 2002478]
SF-268	IC₅₀	7.68 x 10^-3 μM Compound: Cytarabine	Cytotoxicity against human SF268 cells by MTT assay Cytotoxicity against human SF268 cells by MTT assay	[PMID: 19345581]
SF-268	IC₅₀	7.68 μM Compound: Cytarabine	Cytotoxicity against human SF268 cells after 3 days by MTT assay Cytotoxicity against human SF268 cells after 3 days by MTT assay	[PMID: 20356655]
SK-BR-3	IC₅₀	0.87 μM Compound: ara-C	Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
SK-ES1	IC₅₀	0.09 μg/mL Compound: 2	In vitro inhibitory effect measured against human osteosarcoma SK-ES-1 tumor cells In vitro inhibitory effect measured against human osteosarcoma SK-ES-1 tumor cells	[PMID: 2002478]
SK-HEP1	IC₅₀	2.12 μM Compound: Ara-C	Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
SK-HEP1	IC₅₀	1.8 μM Compound: Ara-C	Cytotoxicity against human SKHEP1 cells assessed as decrease in cell viability after 72 hrs by SRB assay Cytotoxicity against human SKHEP1 cells assessed as decrease in cell viability after 72 hrs by SRB assay	[PMID: 29906687]
SK-MEL-28	IC₅₀	1 μM Compound: Ara-C	In vitro cytotoxicity was evaluated against melanoma SK-MEL-28 cells In vitro cytotoxicity was evaluated against melanoma SK-MEL-28 cells	[PMID: 10780904]
SK-MEL-28	IC₅₀	11.1 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human melanoma (P-36) cell line. In vitro inhibitory activity against Human melanoma (P-36) cell line.	[PMID: 1995905]
SK-OV-3	IC₅₀	0.99 μM Compound: ara-C	Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
Small cell lung cancer cell line	IC₅₀	>100 μM Compound: ara-C	Compound was tested for the inhibition of small cell lung cancer Compound was tested for the inhibition of small cell lung cancer	[PMID: 3761322]
SMMC-7721	IC₅₀	0.013 μM Compound: ARA	Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 29886320]
SMMC-7721	IC₅₀	0.0271 μM Compound: ARA	Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay	[PMID: 30852384]
SNB-7	IC₅₀	1 μM Compound: Ara-C	In vitro cytotoxicity was evaluated againstCNS SNB-7 cells; 1 x 10E1 In vitro cytotoxicity was evaluated againstCNS SNB-7 cells; 1 x 10E1	[PMID: 10780904]
SNU-638	IC₅₀	0.15 μM Compound: 1, ara-C	Cytotoxicity against human SNU638 cells by sulforhodamine B method Cytotoxicity against human SNU638 cells by sulforhodamine B method	[PMID: 19691349]
SNU-638	IC₅₀	0.15 μM Compound: 2, Ara-C	Cytotoxicity against human SNU638 cells by SRB assay Cytotoxicity against human SNU638 cells by SRB assay	[PMID: 24956556]
SNU-638	IC₅₀	3.98 μM Compound: Ara-C	Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
SNU-638	IC₅₀	1.08 μM Compound: Ara-C	Cytotoxicity against human SNU638 cells assessed as decrease in cell viability after 72 hrs by SRB assay Cytotoxicity against human SNU638 cells assessed as decrease in cell viability after 72 hrs by SRB assay	[PMID: 29906687]
SNU-638	IC₅₀	0.15 μM Compound: AraC	Cytotoxicity against human SNU-638 cells Cytotoxicity against human SNU-638 cells	[PMID: 38716896]
ST-KM-1	IC₅₀	>410 μM Compound: ara-c	Tested in vitro against ST-KM human stomach adenocarcinoma Tested in vitro against ST-KM human stomach adenocarcinoma	[PMID: 8277499]
SW1573	IC₅₀	10500 μM Compound: cytarabine	Cytotoxicity against SW1573 cells after 72 hrs by SRB assay Cytotoxicity against SW1573 cells after 72 hrs by SRB assay	[PMID: 17419604]
SW48	IC₅₀	>410 μM Compound: ara-c	Tested in vitro against SW-48 human colon adenocarcinoma Tested in vitro against SW-48 human colon adenocarcinoma	[PMID: 8277499]
SW480	ED₅₀	3.42 μg/mL Compound: cytosine arabinoside	Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
SW480	IC₅₀	>100 μg/mL Compound: ara-C	Concentration required for 50% inhibition of human lung squamous cell carcinoma SW 480 solid cell lines. Concentration required for 50% inhibition of human lung squamous cell carcinoma SW 480 solid cell lines.	[PMID: 1992123]
SW480	IC₅₀	>100 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human colon adenocarcinoma (SW-480) cell line. In vitro inhibitory activity against Human colon adenocarcinoma (SW-480) cell line.	[PMID: 1995905]
SW480	IC₅₀	>100 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human colon adenocarcinoma cell lines (SW480). In vitro inhibitory effect on growth of human colon adenocarcinoma cell lines (SW480).	[PMID: 3373480]
SW-620	IC₅₀	30 μM Compound: Ara-C	Antitumor activity against human SW620 cells after 24 hrs by MTT assay Antitumor activity against human SW620 cells after 24 hrs by MTT assay	[PMID: 20211564]
T-24	IC₅₀	>100 μg/mL Compound: ara-C	Concentration required for 50% inhibition of human lung squamous cell carcinoma T24 solid cell lines. Concentration required for 50% inhibition of human lung squamous cell carcinoma T24 solid cell lines.	[PMID: 1992123]
T-24	IC₅₀	0.5 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human bladder transitional-cell carcinoma (T-24) cell line. In vitro inhibitory activity against Human bladder transitional-cell carcinoma (T-24) cell line.	[PMID: 1995905]
T-24	IC₅₀	0.5 μg/mL Compound: 2	In vitro inhibitory effect measured against human bladder transitional cell carcinoma T-24 tumor cells In vitro inhibitory effect measured against human bladder transitional cell carcinoma T-24 tumor cells	[PMID: 2002478]
T-24	IC₅₀	>100 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human bladder transitional-carcinoma cell lines (T24). In vitro inhibitory effect on growth of human bladder transitional-carcinoma cell lines (T24).	[PMID: 3373480]
T47D	IC₅₀	2.7 μM Compound: 1, ara-C	Cytotoxicity against human T47D cells by sulforhodamine B method Cytotoxicity against human T47D cells by sulforhodamine B method	[PMID: 19691349]
T47D	IC₅₀	2.72 μM Compound: 2, Ara-C	Cytotoxicity against human T47D cells by SRB assay Cytotoxicity against human T47D cells by SRB assay	[PMID: 24956556]
T47D	IC₅₀	2.7 μM Compound: AraC	Cytotoxicity against human T47D cells Cytotoxicity against human T47D cells	[PMID: 38716896]
TE-2	IC₅₀	>100 μg/mL Compound: ara-C	Concentration required for 50% inhibition of human lung squamous cell carcinoma TE2 solid cell lines. Concentration required for 50% inhibition of human lung squamous cell carcinoma TE2 solid cell lines.	[PMID: 1992123]
TE-2	IC₅₀	>100 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human esophagus adenocarcinoma (TE-2) cell line. In vitro inhibitory activity against Human esophagus adenocarcinoma (TE-2) cell line.	[PMID: 1995905]
TE-2	IC₅₀	>100 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human esophagus adenocarcinoma cell lines (TE2). In vitro inhibitory effect on growth of human esophagus adenocarcinoma cell lines (TE2).	[PMID: 3373480]
U-87MG ATCC	IC₅₀	2.88 μM Compound: ara-C	Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
U-87MG ATCC	IC₅₀	0.85 μM Compound: ara-C	Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
U-87MG ATCC	CC₅₀	0.19 μM Compound: 16	Cytotoxicity against human U-87 MG cells measured after 3 days by Celltiter-glo assay Cytotoxicity against human U-87 MG cells measured after 3 days by Celltiter-glo assay	[PMID: 35123007]
U-937	IC₅₀	0.31 μg/mL Compound: ara-C	Concentration required for 50% inhibition of cell growth of U937 leukemic cell lines in human. Concentration required for 50% inhibition of cell growth of U937 leukemic cell lines in human.	[PMID: 1992123]
U-937	IC₅₀	0.46 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human histiocytic lymphoma (U-937) cell line. In vitro inhibitory activity against Human histiocytic lymphoma (U-937) cell line.	[PMID: 1995905]
U-937	IC₅₀	0.002 μM Compound: Cytarabine	Cytotoxicity against human U937 cells assessed as reduction in cell viability measured after 3 days by CCK8 assay Cytotoxicity against human U937 cells assessed as reduction in cell viability measured after 3 days by CCK8 assay	[PMID: 30954427]
Vero	CC₅₀	4.8 μg/mL Compound: Ara-C	Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay	[PMID: 12444692]
Vero	EC₅₀	1.6 μg/mL Compound: Ara-C	Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	[PMID: 12444692]
Vero	EC₅₀	3 μg/mL Compound: Ara-C	Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	[PMID: 12444692]
WI-38	IC₅₀	>100 μg/mL Compound: CAR	Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay	[PMID: 35963130]
WI-38	IC₅₀	493.17 μM Compound: CAR	Cytotoxicity against human WI-38 cells incubated for 48 hrs by MTT assay Cytotoxicity against human WI-38 cells incubated for 48 hrs by MTT assay	[PMID: 38516604]

In Vitro

Cytarabine is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Cytarabine displays a higher growth inhibitory activity towards wild-type CCRF-CEM cells compared to other acute myelogenous leukemia (AML) cells with IC₅₀ of 16 nM^[1].
Cytarabine apparently induces apoptosis of rat sympathetic neurons at 10 μM, of which 100 μM shows the highest toxicity and kills over 80% of the neurons by 84 hours, involving the release of mitochondrial cytochrome-c and the activation of caspase-3, and the toxicity can be attenuated by p53 knockdown and delayed by bax deletion^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cytarabine (250 mg/kg) also causes placental growth retardation and increases placental trophoblastic cells apoptosis in the placental labyrinth zone of the pregnant Slc:Wistar rats, which increases from 3 hour after the treatment and peaks at 6 hour before returning to control levels at 48 hour, with remarkably enhanced p53 protein, p53 trancriptional target genes such as p21, cyclinG1 and fas and caspase-3 activity^[3].
Cytarabine is highly effective against acute leukaemias, which causes the Cytarabine teristic G1/S blockage and synchronization, and increases the survival time for leukaemic Brown Norway rats in a weak dose-related fashion indicating that the use of higher dosages of Cytarabine does not contribute to its antileukaemic effectiveness in man^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 147-94-4
Appearance Solid
Molecular Weight 243.22
Formula C₉H₁₃N₃O₅
Color White to off-white
SMILES

O=C1N=C(C=CN1[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)N
Synonyms

Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; Ara-C
Structure Classification
- Others
Initial Source
- Marine natural products
- Sponge
- Microorganisms
- Endogenous metabolite
Xerocomus nigromaculatus
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (100)

All Cell Proliferation/Viability AssayWB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Science

Subventricular zone radial glial cells maintain inhibitory neuron production in the human brain. [Abstract]

2026 Jan 15;391(6782):eadw1803. PMID: 41538440
Cancer Cell

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. [Abstract]

2023 Dec 11;41(12):2136-2153.e13. PMID: 37995682
Cell

Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. [Abstract]

2018 Sep 20;175(1):171-185.e25. PMID: 30146162
Immunity

Bi-directional communication between intrinsic enteric neurons and ILC2s inhibits host defense against helminth infection. [Abstract]

2025 Feb 11;58(2):465-480.e8. PMID: 39889704
Cell Stem Cell

Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. [Abstract]

2026 Jun 4;33(6):982-999.e8. PMID: 42102807
Nat Cell Biol

Trafficking circuit of CD8+ T cells between the intestine and bone marrow governs antitumour immunity. [Abstract]

2024 Aug;26(8):1346-1358. PMID: 39039181
Nat Commun

Hematopoietic stem and progenitor cell membrane-coated vesicles for bone marrow-targeted leukaemia drug delivery. [Abstract]

2024 Jul 7;15(1):5689. PMID: 38971796
Cell Death Differ

Inhibition of cGAS-STING by JQ1 alleviates oxidative stress-induced retina inflammation and degeneration. [Abstract]

2022 Sep;29(9):1816-1833. PMID: 35347235
Transl Neurodegener

Neuronal double-stranded DNA accumulation induced by DNase II deficiency drives tau phosphorylation and neurodegeneration. [Abstract]

2024 Aug 2;13(1):39. PMID: 39095921
Leukemia

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. [Abstract]

2023 Jun;37(6):1336-1348. PMID: 36977823
Leukemia

Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness. [Abstract]

2021 Oct;35(10):2827-2839. PMID: 33782537

Cytarabine purchased from MedChemExpress. Usage Cited in: Leukemia. 2021 Oct;35(10):2827-2839. [Abstract]

TF-1 clones are incubated with 2 µM Cytarabine (araC) for up to 10 or 12 h, and cleaved caspase-3 is detected by immunoblot analysis.

Cytarabine purchased from MedChemExpress. Usage Cited in: Leukemia. 2021 Oct;35(10):2827-2839. [Abstract]

TF-1 clones were incubated with 2 µM araC or 1 µM DNR for up to 10 or 12 h, respectively, and cleaved caspase-3 was detected by immunoblot analysis. GAPDH was used as loading control.
J Adv Res

Dynamic heterogeneity towards drug resistance in AML cells is primarily driven by epigenomic mechanism unveiled by multi-omics analysis. [Abstract]

2025 May 21:S2090-1232(25)00358-3. PMID: 40409464
J Adv Res

Antimycin A inhibits alpha-herpesvirus replication by disrupting the formation of pyrimidinosomes. [Abstract]

2025 May 10:S2090-1232(25)00309-1. PMID: 40354935
J Exp Clin Cancer Res

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax. [Abstract]

2022 Dec 9;41(1):340. PMID: 36482393
J Nanobiotechnology

A structured biomimetic nanoparticle as inflammatory factor sponge and autophagy-regulatory agent against intervertebral disc degeneration and discogenic pain. [Abstract]

2024 Aug 14;22(1):486. PMID: 39143545
Sci Adv

Ara-C suppresses H3 K27-altered spinal cord diffuse midline glioma growth and enhances immune checkpoint blockade sensitivity. [Abstract]

2025 Apr 18;11(16):eadu3956. PMID: 40238864
Cell Discov

Reprogramming of palmitic acid induced by dephosphorylation of ACOX1 promotes β-catenin palmitoylation to drive colorectal cancer progression. [Abstract]

2023 Mar 7;9(1):26. PMID: 36878899
Blood Cancer Discov

Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia. [Abstract]

2026 Jul 1;7(4):624-641. PMID: 42149820
Blood Cancer Discov

An Isoform-Specific RUNX1C-BTG2 Axis Governs AML Quiescence and Chemoresistance. [Abstract]

2025 Sep 3;6(5):464-483. PMID: 40632085
Cell Rep Med

Sequence-dependent splicing dysregulation drives therapy resistance in pediatric AML. [Abstract]

2026 Jan 20;7(1):102542. PMID: 41564858
Cell Rep Med

FLT3L-based drug conjugate effectively targets chemoresistant leukemia stem cells in acute myeloid leukemia. [Abstract]

2025 Sep 19:102365. PMID: 40975063
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Cell Rep Med

Modeling high-risk Wilms tumors enables the discovery of therapeutic vulnerability. [Abstract]

2024 Sep 27:101770. PMID: 39368485

Cytarabine purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Sep 27:101770. [Abstract]

Cell viability of WiT49-parental and WiT49-PRC-1 cells treated with cytarabine. IC50 is shown in the figure. The WiT49-PRC-1 cells are 100-fold more sensitive to cytarabine and 20-fold more sensitive to alisertib than the parental WiT49 cells.
Cell Rep Med

A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. [Abstract]

2024 May 29:101592. PMID: 38843841
Cancer Lett

ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer. [Abstract]

2023 Jan 1:552:215981. PMID: 36341997
Adv Healthc Mater

Biomimetic Copper-Doped Nano-Aluminum Adjuvant Potentiates Therapy in Chemoresistant Acute Myeloid Leukemia. [Abstract]

2026 Mar 10:e04039. PMID: 41804653
Cell Death Dis

The ALDH2/PolG2 axis enhances mitochondrial biogenesis via transcriptional regulation of Nrf2 and promotes chemotherapy resistance in acute myeloid leukaemia. [Abstract]

2025 Aug 13;16(1):616. PMID: 40796730
Acta Biomater

Nucleus pulposus cell-mimicking nanoparticles for cell-specific HIF1A editing to modulate SASP-mediated disc inflammation via autophagy activation. [Abstract]

2025 May 1:197:357-373. PMID: 40087134
Acta Biomater

Multifunctional annulus fibrosus matrix prevents disc-related pain via inhibiting neuroinflammation and sensitization. [Abstract]

2023 Oct 15:170:288-302. PMID: 37598791
Cell Death Dis

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis. [Abstract]

2022 Apr 20;13(4):379. PMID: 35443722
Cell Death Dis

Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2. [Abstract]

2021 Jan 5;12(1):20. PMID: 33414469
Int J Biol Macromol

Exosomal microRNA-20b-5p contributes to cytarabine resistance in acute myeloid leukemia via the microtubule-associated serine/threonine kinase-like-phosphatidylinositol 3-kinase-protein kinase B signaling axis. [Abstract]

2025 Dec;333(Pt 2):148750. PMID: 41197693
Acta Pharmacol Sin

Bardoxolone displays potent activity against triple negative breast cancer by inhibiting the TRIP13/STAT3 circuit. [Abstract]

2025 Jun;46(6):1733-1741. PMID: 39939802
Acta Pharmacol Sin

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]

2021 Jan;42(1):108-114. PMID: 32398685
Free Radic Biol Med

Optineurin enhances the chemoresistance by activating mitophagy in acute myeloid leukemia with NPM1 mutation. [Abstract]

2026 May:248:162-176. PMID: 41722661
ACS Appl Mater Interfaces

Carrier-Free Nanoplatform via Evoking Pyroptosis and Immune Response against Breast Cancer. [Abstract]

2023 Jan 11;15(1):452-468. PMID: 36538368
Br J Pharmacol

The fast-dissociating D2 antagonist antipsychotic JNJ-37822681 is a neuronal Kv7 channel opener: Potential repurposing for epilepsy treatment. [Abstract]

2025 Jul 23. PMID: 40702669
Blood Adv

CBFA2T3::GLIS2 Pediatric Acute Megakaryoblastic Leukemia is Sensitive to BCL-XL Inhibition by Navitoclax and DT2216. [Abstract]

2024 Jan 9;8(1):112-129. PMID: 37729615
Cell Rep

A generalized strategy to kill leukemic cells by targeting the regulatory systems governing mitochondrial membrane potential. [Abstract]

2025 Nov 25;44(11):116496. PMID: 41166305
Sci Data

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]

2024 Sep 19;11(1):1024. PMID: 39300112
Clin Chem

Discovering Cross-Reactivity in Urine Drug Screening Immunoassays through Large-Scale Analysis of Electronic Health Records. [Abstract]

2019 Dec;65(12):1522-1531. PMID: 31578215
Antioxid Redox Signal

Exosomal miR-196a-5p Secreted by Bone Marrow Mesenchymal Stem Cells Inhibits Ferroptosis and Promotes Drug Resistance of Acute Myeloid Leukemia. [Abstract]

2025 Jun;42(16-18):933-953. PMID: 40388337
Cancer Cell Int

GANT61 surmounts drug resistance of ADR by upregulating lysosome activities and reducing BCL2 expression in HL-60/ADR cells. [Abstract]

2024 Dec 26;24(1):430. PMID: 39726048
Biochem Pharmacol

Mutant NPM1-regulated estrogen signaling promotes leukemia cell survival by upregulating HGF and represents a therapeutic vulnerability. [Abstract]

2026 May:247:117796. PMID: 41679667
Biochem Pharmacol

Deubiquitinase USP5 promotes acute myeloid leukemia through C2CD5 stabilization and PI3K/AKT/mTOR/HIF-1α-driven glycolysis. [Abstract]

2026 Feb:244:117591. PMID: 41344512
Ocul Surf

Cytarabine chemotherapy induces meibomian gland dysfunction. [Abstract]

2024 Oct:34:444-458. PMID: 39395739
Biochem Pharmacol

The new mitochondrial uncoupler BAM15 induces ROS production for treatment of acute myeloid leukemia. [Abstract]

2022 Apr:198:114948. PMID: 35192847
Arab J Chem

2023 Jul 4, 105117.
Life Sci

A protective role of ECSIT in chemotherapy-induced intestinal mucositis by maintaining Lgr5+ intestinal stem cells and gut homeostasis. [Abstract]

2026 Mar 15:389:124236. PMID: 41611204
Stem Cell Reports

Cell cycle heterogeneity directs spontaneous 2C state entry and exit in mouse embryonic stem cells. [Abstract]

2021 Nov 9;16(11):2659-2673. PMID: 34624246
Eur J Pharmacol

Quizartinib-induced resistance drives clonal emergence of MV4-11 cells with molecular alterations enabling multidrug antileukemic escape. [Abstract]

2026 May 10:1023:178877. PMID: 41997407
Eur J Pharmacol

Lycorine eliminates B-cell acute lymphoblastic leukemia cells by targeting PSAT1 through the serine/glycine metabolic pathway. [Abstract]

2023 Dec 15:961:176162. PMID: 37951487
Eur J Pharmacol

Overexpressed mitogen-and stress-activated protein kinase 1 promotes the resistance of cytarabine in acute myeloid leukemia through brahma related gene 1-mediated upregulation of heme oxygenase-1. [Abstract]

2022 Feb 15:917:174722. PMID: 34953799
J Med Virol

Drug Repurposing: In Vitro Evaluation of Simeprevir as a Novel Antiviral Drug Against Severe Fever With Thrombocytopenia Syndrome Virus. [Abstract]

2025 Oct;97(10):e70655. PMID: 41117261
Cancer Biol Ther

Caspase 3-specific cleavage of ubiquitin-specific peptidase 48 enhances drug-induced apoptosis in AML. [Abstract]

2025 Dec;26(1):2459426. PMID: 39878157
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Mol Pharm

Evaluation of the Anticancer Activity of pH-Sensitive Polyketal Nanoparticles for Acute Myeloid Leukemia. [Abstract]

2021 May 3;18(5):2015-2031. PMID: 33780253
Cancers (Basel)

Association between Dysfunction of the Nucleolar Stress Response and Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia. [Abstract]

2022 Oct 19;14(20):5127. PMID: 36291909
Mol Neurobiol

Ox-LDL Induces Neuron Apoptosis and Worsens Neurological Outcomes in aSAH via Fas/FADD Pathway. [Abstract]

2025 Apr 8. PMID: 40199806
Biochim Biophys Acta Mol Basis Dis

INSR/AKT1 axis promotes cells proliferation and migration in acute myeloid leukemia. [Abstract]

2025 Dec 13;1872(3):168132. PMID: 41397617
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
J Inflamm Res

Wnt3a Inhibits Inflammatory Responses and Improves Survival in Immortalised Schwann Cells. [Abstract]

2025 Dec 18:18:17715-17730. PMID: 41439129
iScience

RHOF activation of AKT/β-catenin signaling pathway drives acute myeloid leukemia progression and chemotherapy resistance. [Abstract]

2024 Jun 8;27(7):110221. PMID: 39021805
Sci Rep

AAD-2004 through clearing H2O2 reduces astrocyte proliferation and promotes neural regeneration after spinal cord injury. [Abstract]

2025 Dec 26. PMID: 41454086
J Biol Chem

Nuclear factor Nrf2 promotes glycosidase OGG1 expression by activating the AKT pathway to enhance leukemia cell resistance to cytarabine. [Abstract]

2023 Jan;299(1):102798. PMID: 36528059
Fish Shellfish Immunol

Tiger frog virus ORF104R interacts with cellular VDAC2 to inhibit cell apoptosis. [Abstract]

2019 Sep;92:889-896. PMID: 31299465
ACS Infect Dis

Targeting the Rift Valley Fever Virus Polymerase: Resistance Mechanisms and Structural Insights. [Abstract]

2025 Oct 30. PMID: 41166549
J Virol

Neurovirulence of avian influenza virus is dependent on the interaction of viral NP protein with host factor FMRP in the murine brain. [Abstract]

2021 Mar 10;95(7):e01272-20. PMID: 33408179
Insect Biochem Mol Biol

Replication and transcription of eccDNAfib-L, an extrachromosomal circular DNA in the silk gland of silkworm, Bombyx mori. [Abstract]

2025 Oct 17:185:104424. PMID: 41110800
Biomed Mater

Three-dimensional porous composite scaffolds for in vitro marrow microenvironment simulation to screen leukemia drug. [Abstract]

2020 Apr 28;15(3):035016. PMID: 32045893
Heliyon

GPRASP2 deficiency contributes to apoptosis in the spiral ganglion cells via the AMPK/DRP1 signaling pathway. [Abstract]

2024 Aug 13;10(16):e36140. PMID: 39253164
Toxicol Appl Pharmacol

Flavokawain a induces cell cycle arrest through CDT1-dependent p27 regulation and synergizes with venetoclax in acute myeloid leukemia. [Abstract]

2025 May:498:117305. PMID: 40113097

Cytarabine purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2025 May:498:117305. [Abstract]

FKA (Flavokawain A; HY-N2420) decreases the viability in AML cell lines. MV4-11, MOLM-13, THP-1, and U937 cells were treated with or without various concentrations of FKA (2.5, 5, 10, and 20 μg/mL) for 24 and 48 h, and cell viability was detected by the MTS assay. Treatment with Cytarabine (HY-13605; 7.3 μg/mL) was used as a positive control.

Cytarabine purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2025 May:498:117305. [Abstract]

FKA (Flavokawain A; HY-N2420) targets primary AML blasts. Samples from AML patients were treated with or without various concentrations of FKA (2.5, 5, 10, and 20 μg/mL) for 48 h, and cell viability was detected by the MTS assay. Treatment with Cytarabine (HY-13605) was used as a positive control. Data were shown as mean ± SD from at least three independent experiments.
Front Oncol

Hypoxanthine in the microenvironment can enable thiopurine resistance in acute lymphoblastic leukemia. [Abstract]

2024 Jul 19:14:1440650. PMID: 39099696
Neurotox Res

MiRNA-494-3p Regulates Bupivacaine-Induced Neurotoxicity by the CDK6-PI3K/AKT Signaling. [Abstract]

2021 Dec;39(6):2007-2017. PMID: 34652691
Mol Carcinog

Integrated Genomics Reveal Potential Resistance Mechanisms of PANoptosis-Associated Genes in Acute Myeloid Leukemia. [Abstract]

2025 May;64(5):801-815. PMID: 39868611
Mol Carcinog

circSLC25A13 acts as a ceRNA to regulate AML progression via miR-616-3p/ADCY2 axis. [Abstract]

2023 Oct;62(10):1546-1562. PMID: 37493101
J Leukoc Biol

Hypoxia-activated cystathionine β-synthase/H2S signaling drives drug resistance in acute myeloid leukemia through CD36-mediated fatty acid metabolism. [Abstract]

2025 May 16:qiaf065. PMID: 40376852
Mol Brain

LRP4 LDLα repeats of astrocyte enhance dendrite arborization of the neuron. [Abstract]

2020 Dec 10;13(1):166. PMID: 33302985
Front Genet

The Prognostic Value and Function of HOXB5 in Acute Myeloid Leukemia. [Abstract]

2021 Aug 5:12:678368. PMID: 34421991
SLAS Discov

A Multiplexed Screening Assay to Evaluate Chemotherapy-Induced Myelosuppression Using Healthy Peripheral Blood and Bone Marrow. [Abstract]

2018 Aug;23(7):687-696. PMID: 29865911
Stem Cells Dev

Effects of Complex I Inhibition on the Architecture of Neural Rosettes Differentiated from Human-Induced Pluripotent Stem Cells. [Abstract]

2025 Apr;34(7-8):164-176. PMID: 40079171
Biol Pharm Bull

RSK Inhibition Induces Apoptosis by Downregulating Protein Synthesis in a Variety of Acute Myeloid Leukemia Cell Lines. [Abstract]

2021 Dec 1;44(12):1843-1850. PMID: 34602526
Curr Med Sci

Targeting Calprotectin S100A8/A9 to Overcome AML Progression in DNMT3A-Mutant Cells. [Abstract]

2025 Apr 23. PMID: 40266434
Res Sq

2026 Jun 15.
Res Sq

Dual-functional Nanocarrier for Improved Immunochemotherapy of Acute Myeloid Leukemia. [Abstract]

2026 Jun 18:rs.3.rs-9901177. PMID: 42370261
bioRxiv

2026 Feb 20.
bioRxiv

2026 Feb 12.
Patent

US20240344035A1
Research Square Preprint

2024 Aug 19.
Patent

US20240344035A1.
bioRxiv

2024 September 19.
Res Sq

2024 Jul 12.
bioRxiv

2024 June 28.
bioRxiv

Targetable leukemia dependency on noncanonical PI3Kγ signaling. [Abstract]

2023 Dec 15:2023.12.15.571909. PMID: 38328043
Research Square Preprint

2023 Oct 28.
Universidad De Salamanca

2023
Asian Pac J Cancer Prev

Quantitative Profiling of Alpha-Subunit of IL-3 Receptor on Single Acute Myeloid Leukemia Cells by Super-Resolution Imaging. [Abstract]

2023 Jan 1;24(1):185-194. PMID: 36708567
Research Square Print

September 9th, 2022.
Research Square Preprint

2022 Jun.

Solvent & Solubility

In Vitro:

DMSO : 17.3 mg/mL (71.13 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.1115 mL

20.5575 mL

41.1150 mL

5 mM

0.8223 mL

4.1115 mL

8.2230 mL

10 mM

0.4112 mL

2.0558 mL

4.1115 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (8.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (8.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (8.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (411.15 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Animal Administration^[3]

Pregnant rats are injected intraperitoneally (i.p.) with 250 mg/kg of Cytarabine on Day 13 of gestation (GD13). Under the conditions of this experiment, congenital anomalies and growth retardation are detected at a high rate in perinatal fetuses, although the incidence of fetal death is not markedly increased. At 1, 3, 6, 9, 12, 24, and 48 h after the treatment, six dams each are killed by heart puncture under ether anesthesia, and the placentas are collected. As controls, six pregnant rats are injected i.p. with an equivalent volume of PBS on GD13 and killed at the same time point as Cytarabine-treated groups. Of the six dams obtained at each time point, three are used for histopathological analyses and three for reverse transcription-polymerase chain reaction (RT-PCR) analysis.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Portuguese - PT (557 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Tobias, S.C. and R.F. Borch, Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol Pharm, 2004. 1(2): p. 112-6. [Content Brief]

[2]. Besirli, C.G., et al. Cytosine arabinoside rapidly activates Bax-dependent apoptosis and a delayed Bax-independent death pathway in sympathetic neurons. Cell Death Differ, 2003. 10(9): p. 1045-58. [Content Brief]

[3]. Yamauchi, H., et al., Involvement of p53 in 1-beta-D-arabinofuranosylcytosine-induced trophoblastic cell apoptosis and impaired proliferation in rat placenta. Biol Reprod, 2004. 70(6): p. 1762-7. [Content Brief]

[4]. Richel, D.J., et al., Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. Br J Cancer, 1988. 58(6): p. 730-3. [Content Brief]

[5]. Shepshelovich D, et al. Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study. Br J Clin Pharmacol. 2015 Apr;79(4):685-91. [Content Brief]

[6]. Renis HE. Antiviral activity of cytarabine in herpesvirus-infected rats. Antimicrob Agents Chemother. 1973 Oct;4(4):439-44. [Content Brief]

[7]. Gruffaz M, Zhou S, Vasan K, et al. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications. mBio. 2018;9(3):e00756-18. Published 2018 May 8. [Content Brief]

[8]. Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.1115 mL	20.5575 mL	41.1150 mL	102.7876 mL
	5 mM	0.8223 mL	4.1115 mL	8.2230 mL	20.5575 mL
	10 mM	0.4112 mL	2.0558 mL	4.1115 mL	10.2788 mL
	15 mM	0.2741 mL	1.3705 mL	2.7410 mL	6.8525 mL
	20 mM	0.2056 mL	1.0279 mL	2.0558 mL	5.1394 mL
	25 mM	0.1645 mL	0.8223 mL	1.6446 mL	4.1115 mL
	30 mM	0.1371 mL	0.6853 mL	1.3705 mL	3.4263 mL
	40 mM	0.1028 mL	0.5139 mL	1.0279 mL	2.5697 mL
	50 mM	0.0822 mL	0.4112 mL	0.8223 mL	2.0558 mL
	60 mM	0.0685 mL	0.3426 mL	0.6853 mL	1.7131 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Cytarabine

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Nucleotide Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Microbial Metabolite Library

Food-Sourced Compound Library

Targeted Diversity Library

Rare Diseases Drug Library

Pediatric Drug Library

Anti-Cancer Natural Product Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Orthopoxvirus Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Marine-Sourced Natural Product Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Cytarabine

All DNA/RNA Synthesis Isoforms

All HSV Isoforms

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (100)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Cytarabine Related Classifications

Cat. No.: HY-13605